EQS-News: AXIM Biotech / Key word (s): Financial AXIM Biotechnologies Submits 510 (k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease 06.10.2026 / 15:00 ...

The Parisian pharmaceutical laboratory rebounds in mid-morning trading, within a rising CAC 40 index. This recovery comes ...

The financing includes a Series A and up to $20 million in non-dilutive funding from the Government of Slovakia and the ...

Adaptive Biotechnologies Corp’s stock reached a 52-week high, hitting $30.10, marking a significant milestone for the company ...

Learn more about whether Adaptive Biotechnologies Corporation or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Burgundy biotech company specializing in fibrotic and metabolic diseases is declining again at mid-day, just days after ...

Fintel reports that on 29 September 2026, Goldman Sachs initiated coverage of Adaptive Biotechnologies (MUN:1HM) with a Buy recommendation. Adaptive Biotechnologies Corporation, based in the United ...

The average one-year price target for Adaptive Biotechnologies (NASDAQGS:ADPT) (MUN:1HM) has been revised to $28.05 / share. This is an increase of 11.11% from the prior estimate of $25.24 dated ...

View Adaptive Biotechnologies Corp. ADPT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Guggenheimanalyst Subbu Nambi maintains $Adaptive Biotechnologies(ADPT.US)$ with a buy rating, and adjusts the target price ...

Adaptive Biotechnologies Corporation (ADPT) is down 3.5% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not fully clear, but the move appears ...

Bio-Rad Laboratories tumbled 5.2% on Thursday as a sector-wide selloff dragged down medical device and life sciences stocks ...